This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McSharry, J. J.
Right arrow Articles by Biron, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McSharry, J. J.
Right arrow Articles by Biron, K. K.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1279-1281, Vol. 8, No. 6
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.6.1279-1281.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Inhibition of Ganciclovir-Susceptible and -Resistant Human Cytomegalovirus Clinical Isolates by the Benzimidazole L-Riboside 1263W94

James J. McSharry,1,* Ann McDonough,1 Betty Olson,1 Christine Talarico,2 Michele Davis,2 and Karen K. Biron2

Albany Medical College, Albany, New York,1 and GlaxoSmithKline, Research Triangle Park, North Carolina2

Received 25 May 2001/Returned for modification 5 June 2001/Accepted 20 August 2001

The average 50% inhibitory concentration (IC50) values for AD169 were 0.22 ± 0.09 µM 1263W94 and 5.36 ± 0.12 µM ganciclovir. For 35 human cytomegalovirus (HCMV) clinical isolates the average IC50 was 0.42 ± 0.09 µM 1263W94, and for 26 ganciclovir-susceptible HCMV clinical isolates the average IC50 was 3.78 ± 1.62 µM ganciclovir. Nine HCMV clinical isolates that were resistant to ganciclovir were completely susceptible to 1263W94.


* Corresponding author. Mailing address: Center for Immunology and Microbial Disease, Albany Medical College, Mail Code 151, 47 New Scotland Ave., Albany, NY 12208. Phone: (518) 262-5174. Fax: (518) 262-5748. E-mail: mcsharj{at}mail.amc.edu.


Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1279-1281, Vol. 8, No. 6
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.6.1279-1281.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Murayama, T., Yamaguchi, N., Matsuno, H., Eizuru, Y. (2004). In Vitro Anti-Cytomegalovirus Activity of Kampo (Japanese Herbal) Medicine. Evid Based Complement Alternat Med 1: 285-289 [Abstract] [Full Text]  
  • Herget, T., Freitag, M., Morbitzer, M., Kupfer, R., Stamminger, T., Marschall, M. (2004). Novel Chemical Class of pUL97 Protein Kinase-Specific Inhibitors with Strong Anticytomegaloviral Activity. Antimicrob. Agents Chemother. 48: 4154-4162 [Abstract] [Full Text]  
  • Kern, E. R., Hartline, C. B., Rybak, R. J., Drach, J. C., Townsend, L. B., Biron, K. K., Bidanset, D. J. (2004). Activities of Benzimidazole D- and L-Ribonucleosides in Animal Models of Cytomegalovirus Infections. Antimicrob. Agents Chemother. 48: 1749-1755 [Abstract] [Full Text]  
  • McSharry, J. J., McDonough, A. C., Olson, B. A., Drusano, G. L. (2004). Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors. CVI 11: 21-28 [Abstract] [Full Text]  
  • Williams, S. L., Hartline, C. B., Kushner, N. L., Harden, E. A., Bidanset, D. J., Drach, J. C., Townsend, L. B., Underwood, M. R., Biron, K. K., Kern, E. R. (2003). In Vitro Activities of Benzimidazole D- and L-Ribonucleosides against Herpesviruses. Antimicrob. Agents Chemother. 47: 2186-2192 [Abstract] [Full Text]  
  • Marschall, M., Stein-Gerlach, M., Freitag, M., Kupfer, R., van den Bogaard, M., Stamminger, T. (2002). Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J. Gen. Virol. 83: 1013-1023 [Abstract] [Full Text]